Is Pfizer Inc (PFE) overvalued? · P/E 20, rev $62.58B
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
This page asks whether Pfizer Inc (PFE) looks expensive on cached numbers — not a short thesis.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
PFE currently screens at market cap $147.73B and trailing P/E 19.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PFE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PFE stock page for the full model, not this heading.
Not investment advice.